|Day Low/High||72.75 / 74.90|
|52 Wk Low/High||56.81 / 77.33|
We are ringing the register this afternoon and declaring victory on DHR ahead of earnings.
Jim discusses Abbott Laboratories' earnings release, his view of the Apple-Qualcomm settlement as it relates to the 5G cycle, several upcoming earnings reports, Anadarko Petroleum, UnitedHealth and much more!
Jim Cramer breaks down what he was watching when Abbott reported earnings Wednesday morning.
This was a very good quarter and the stock performance today is more of a reflection of the hatred for anything healthcare related as well as ABT's already premium valuation.
Abbott reports earnings above its own guidance and that of Wall Street analysts.
Qualcomm and Apple have settled their disputes, and Abbott and Netflix both released earnings.
Jim Cramer weighs in on Abbott's earnings, Qualcomm's dispute with Apple is over and Netflix's earnings.
- Sales and EPS growth exceed guidance; projects strong full-year outlook
China reported positive data, bolstering markets. Netflix had a beat on earnings, but faces fierce competition ahead. CSX is a thing of beauty.
U.S. stock futures rise Wednesday, following on from Tuesday's gains that were spurred on by generally solid earnings reports; Qualcomm surges after the chipmaker ends its long-running dispute with Apple; Netflix's second-quarter forecast disappoints Wall Street; Sprint and T-Mobile slide after a report says their proposed merger is getting resistance form the Justice Department.
They usually run their businesses well, too, Cramer says in revealing his '5 Rules for Trading Stocks During Earnings Season.'
UnitedHealth Group and Johnson & Johnson report Tuesday, Abbott Labs on Wednesday, and Honeywell, Schlumberger and Danaher on Thursday.
Jim Cramer says this positive start will be hard to sustain this earnings season. He's got your game plan for next week.
Funding, rapid diagnostics to address emerging threats of cholera, malaria and other diseases, meet key relief needs in Southeast Africa
Markets move higher as investors shrug off slowing growth to focus on U.S.-China Trade Deal hopes.
We have long cautioned on our member-only conference calls about the flush of IPOs coming to market and its impact to stocks.
Stocks finish week sharply lower on worries over global economic growth slowing after earlier surging on Fed's more accommodating stance.
We are encouraged with CVS Health's plans to fix what has hurt the company and we reiterate that the stock is still inexpensive.
As much as we continue to believe in the company and its strong organic growth trends, discipline calls for us to lock in some of our big gains.
ABBOTT PARK, Ill., March 20, 2019 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its first-quarter 2019 financial results on Wednesday, April 17, 2019, before the market opens.
- Alinity m will allow labs to meet the growing demand for infectious disease testing by offering increased efficiency and market-leading speed and accuracy
- New MOMENTUM 3 data show the best outcomes seen in a randomized controlled clinical trial for left ventricular assist device (LVAD) therapy
- New data presented and simultaneously published in the Journal of the American College of Cardiology show treatment with MitraClip resulted in significant and sustained long-term quality-of-life improvements compared to medical therapy
- The world's first minimally invasive mitral valve repair device now approved to help difficult-to-treat heart failure patients with clinically significant secondary mitral regurgitation
TheStreet’s Fundamentals of Investing Course will teach you the keys to making the right decisions in any market.
TheStreet’s Personal Finance Essentials Course will teach you money management basics and investing strategies to help you avoid major financial pitfalls.
TheStreet Courses offers dedicated classes designed to improve your investing skills, stock market knowledge and money management capabilities.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.